무증상 제2형 당뇨병 환자에서 관상동맥석회 점수와 혈청 osteoprotegerin농도의 상관 관계 = Association of serum osteoprotegerin with coronary artery calcification scores inpatients with asymptomatic type 2 diabetes

다국어 초록 (Multilingual Abstract)

Background/Aims: Osteoprotegerin (OPG), a member of the tumor necrosis factor (TNF) receptor superfamily, is involved in bone metabolism and vascular calcification. However, the relationship between serum OPG levels and coronary calcification is not well elucidated. The present study investigated whether serum OPG levels are associated with coronary artery calcification scores (CACs) in patients with type 2 diabetes. Methods: A total of 140 type 2 diabetic outpatients without previous evidence of clinical cardiovascular disease were recruited. CACs were obtained using multi-slice spiral computed tomography and categorized as minimal (0), mild (1-99), moderate (100-399), or severe (≥400). Serum OPG levels were measured by enzyme-linked immunosorbent assay. Results: A total of 94 of 140 (67.1%) patients with type 2 diabetes showed coronary calcification. A Pearson`s correlation analysis showed a positive correlation between serum OPG levels and CACs. However, multivariate regression analyses revealed that waist circumference, duration of diabetes, and serum creatinine concentration were significant independent determinants of CACs. Conclusions: The present study demonstrates that coronary calcification is common (67.1%), and serum OPG levels are correlated with CACs but are not an independent determinant of CACs in patients with asymptomatic type 2 diabetes. (Korean J Med 79:163-170, 2010)

참고문헌 (Reference)

1 김상욱, "혈액투석 중인 말기 신부전증 환자에서 관상동맥혈관 석회화와 혈청 Osteoprotegerin 및 Fetuin-A 농도의 상관관계" 대한내과학회 72 (72): 451-458, 2007

2 오세용, "제2형 당뇨병 환자에서 혈청 Osteoprotegerin 농도와 인슐린 저항성, 심혈관 질환 위험인자 및 골대사의 연관성" 대한내과학회 68 (68): 168-177, 2005

3 이은정, "관상동맥 환자에서 혈청Osteoprotegerin 농도와 질환 중증도 및 동맥경화 위험 인자와의 연관성" 67 : 365-374, 2004

4 Anand DV, "The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects" 47 : 1850-1857, 2006

5 Jung CH, "The relationship between coronary artery calcification score, plasma osteoprotegerin level and arterial stiffness in asymptomatic type 2 DM" 2009

6 Nitta K, "The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis" 42 : 303-309, 2003

7 Jono S, "Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease" 106 : 1192-1194, 2002

8 Moe SM, "Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD)" 67 : 2295-2304, 2005

9 Shaw LJ, "Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality" 228 : 826-833, 2003

10 Goff DC Jr, "Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial" 99 : 4i-20i, 2007

11 Simonet WS, "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density" 89 : 309-319, 1997

12 Bucay N, "Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification" 12 : 1260-1268, 1998

13 Min H, "Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis" 192 : 463-474, 2000

14 Kiechl S, "Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease" 109 : 2175-2180, 2004

15 Emery JG, "Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL" 273 : 14363-14367, 1998

16 Haffner SM, "Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction" 339 : 229-234, 1998

17 Doherty TM, "Molecular, endocrine, and genetic mechanisms of arterial calcification" 25 : 629-672, 2004

18 Schoppet M, "Increased osteoprotegerin serum levels in men with coronary artery disease" 88 : 1024-1028, 2003

19 Rumberger JA, "Electron beam computed tomography and coronary artery disease: scanning for coronary artery calcification" 71 : 369-377, 1996

20 Mintz GS, "Determinants and correlates of target lesion calcium in coronary artery disease: a clinical, angiographic and intravascular ultrasound study" 29 : 268-274, 1997

21 Wackers FJ, "Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study" 27 : 1954-1961, 2004

22 Rivera JJ, "Detection of occult coronary artery disease in asymptomatic individuals with diabetes mellitus using non-invasive cardiac angiography" 203 : 442-448, 2009

23 Choi EK, "Coronary computed tomography angiography as a screening tool for the detection of occult coronary artery disease in asymptomatic individuals" 52 : 357-365, 2008

24 Goraya TY, "Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study" 40 : 946-953, 2002

25 Ishiyama M, "Associations of coronary artery calcification and carotid intima-media thickness with plasma concentrations of vascular calcification inhibitors in type 2 diabetic patients" 85 : 189-196, 2009

26 Budoff MJ, "Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology" 114 : 1761-1791, 2006

27 Wannamethee SG, "Adipokines and risk of type 2 diabetes in older men" 30 : 1200-1205, 2007